Apr 12, 2013 - From the Sterling Research Group, Cincinnati, OH;1 the University of Alabama at Birmingham, Birmingham, AL;2 Daiichi Sankyo Inc, ...
ORIGINAL
PAPER
Olmesartan/Amlodipine/Hydrochlorothiazide in Obese Participants With Hypertension: A TRINITY Subanalysis Eli M. Roth, MD;1 Suzanne Oparil, MD;2 Michael Melino, PhD;3 James Lee, PhD;3 Victor Fernandez, BS;3 Reinilde Heyrman, MD4 From the Sterling Research Group, Cincinnati, OH;1 the University of Alabama at Birmingham, Birmingham, AL;2 Daiichi Sankyo Inc, Parsippany, NJ;3 and Formerly of Daiichi Sankyo Inc, Parsippany, NJ4
The objective of this prespecified TRINITY study subgroup analysis was to assess the efficacy and safety of triplecombination treatment with olmesartan medoxomil (OM) 40 mg, amlodipine besylate (AML) 10 mg, and hydrochlorothiazide (HCTZ) 25 mg vs the component dual-combination treatments in obese (body mass index [BMI] ≥30 kg/m2) and nonobese (BMI
